SEARCH:   Advanced

Blood, 1 August 2008, Vol. 112, No. 3, pp. 516-518. Prepublished online as a Blood First Edition Paper on May 20, 2008; DOI 10.1182/blood-2008-02-141580. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-02-141580v1 112/3/516    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tam, C. S. Articles by Cortes, J. Search for Related Content PubMed PubMed Citation Articles by Tam, C. S. Articles by Cortes, J. Related Collections Neoplasia Free Research Articles Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia Constantine S. Tam1, Hagop Kantarjian1, Guillermo Garcia-Manero1, Gautam Borthakur1, Susan O'Brien1, Farhad Ravandi1, Jenny Shan1, and Jorge Cortes1 1 Leukemia Department, University of Texas M. D. Anderson Cancer Center, Houston To determine when patients with incomplete responses on second-line tyrosine kinase inhibitor (2TKI) therapy should consider alternative treatment, we analyzed the outcome of 113 patients receiving nilotinib (n = 43) or dasatinib (n = 70) after imatinib failure. After 12 months of 2TKI therapy, patients achieving a major cytogenetic response (12MMCyR) had a significant survival advantage over patients in minor cytogenetic response or complete hematologic response, with a projected one-year survival of 97% and 84% respectively (P = .02). Projected 1-year progression to hematologic failure, accelerated phase, or blast phase was also significantly different (3% vs 17%, P = .003). Early cytogenetic response was strongly predictive of achievement of 12MMCyR, with less than 10% of patients showing no cytogenetic response at 3 to 6 months eventually attaining the target of 12MMCyR. These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF] J. Cortes When Imatinib Fails, What Else Is There? ASCO Educational Book, January 1, 2009; 2009(1): 402 - 406. [Abstract] [Full Text] [PDF] T. O'Hare and M. W. Deininger Toward a Cure For Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2008; 14(24): 7971 - 7974. [Full Text] [PDF] D. Marin, D. Milojkovic, E. Olavarria, J. S. Khorashad, H. de Lavallade, A. G. Reid, L. Foroni, K. Rezvani, M. Bua, F. Dazzi, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood, December 1, 2008; 112(12): 4437 - 4444. [Abstract] [Full Text] [PDF] S. Branford, R. Lawrence, L. Fletcher, C. Field, Z. Rudzki, and T. Hughes The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 331 - 331. [Abstract] [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020